论文部分内容阅读
目的探讨参麦注射液治疗消化道恶性肿瘤化疗后不良反应的效果。方法将中国人民解放军180医院2010年1月1日~2013年1月1日消化道肿瘤术后化疗患者60例随机均分为治疗组与对照组,对照组采用单纯化疗,治疗组在化疗基础上加用参麦注射液,2组均采用folfox6化疗方案(奥沙利铂静滴+氟尿嘧啶静脉泵入+亚叶酸钙静滴)。比较2组的不良反应发生情况。结果治疗组化疗后在神经毒性(56.7%VS 90%)、贫血(33.3%VS 76.7%)、白细胞总数(30%VS 60%)、血小板计数(26.7%VS 46.7%)、AST/ALT(13.3%VS 43.3%)、血糖升高(10%VS 26.7%)、低钾血症(13.4%VS 36.7%)、血液肌酐(0.67%VS 26.7%)、胃肠道反应(33.3%VS 63.3%)、全身乏力(46.7%VS 90%)等不良反应方面较对照组明显降低,2组有显著性差异(P<0.05)。结论参麦注射液在消化道恶性肿瘤术后化疗中能明显减轻化疗不良反应,从而减轻患者的痛苦,值得临床推广使用。
Objective To investigate the effect of Shenmai injection in the treatment of adverse reactions after chemotherapy for digestive tract malignant tumors. Methods Sixty patients undergoing chemotherapy for digestive tract cancer from January 1, 2010 to January 1, 2013 were randomly divided into treatment group and control group. The control group was treated with chemotherapy alone, and the treatment group was treated with chemotherapy. With the addition of Shenmai injection, both groups were treated with a golfox6 chemotherapy regimen (Oxaliplatin intravenous infusion + fluorouracil intravenous pump + leucovorin intravenous infusion). The incidence of adverse reactions was compared between the two groups. Results After treatment, the treatment group had neurotoxicity (56.7%VS 90%), anemia (33.3%VS 76.7%), total white blood cells (30%VS 60%), platelet count (26.7%VS 46.7%), AST/ALT (13.3) %VS 43.3%), elevated blood glucose (10% vs 26.7%), hypokalemia (13.4% vs 36.7%), serum creatinine (0.67% VS 26.7%), gastrointestinal reaction (33.3% VS 63.3%) The adverse reactions such as general malaise (46.7% vs 90%) were significantly lower than those in the control group, and there was a significant difference between the two groups (P<0.05). Conclusion Shenmai injection can significantly reduce the adverse reactions of chemotherapy in postoperative chemotherapy of digestive tract malignant tumors, so as to reduce the suffering of patients and it is worthy of clinical application.